JP2024505964A5 - - Google Patents

Info

Publication number
JP2024505964A5
JP2024505964A5 JP2023546426A JP2023546426A JP2024505964A5 JP 2024505964 A5 JP2024505964 A5 JP 2024505964A5 JP 2023546426 A JP2023546426 A JP 2023546426A JP 2023546426 A JP2023546426 A JP 2023546426A JP 2024505964 A5 JP2024505964 A5 JP 2024505964A5
Authority
JP
Japan
Prior art keywords
adjuvant
administration
peo
poly
polymerosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/052508 external-priority patent/WO2022167497A1/en
Publication of JP2024505964A publication Critical patent/JP2024505964A/ja
Publication of JP2024505964A5 publication Critical patent/JP2024505964A5/ja
Pending legal-status Critical Current

Links

JP2023546426A 2021-02-02 2022-02-02 免疫応答を刺激するための、ポリマーソームと関連づけられたアジュバントの単独使用の方法 Pending JP2024505964A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21154745 2021-02-02
EP21154745.0 2021-02-02
PCT/EP2022/052508 WO2022167497A1 (en) 2021-02-02 2022-02-02 Sole use of polymersome associated adjuvant for stimulating an immune response

Publications (2)

Publication Number Publication Date
JP2024505964A JP2024505964A (ja) 2024-02-08
JP2024505964A5 true JP2024505964A5 (cg-RX-API-DMAC10.html) 2025-02-07

Family

ID=74666418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546426A Pending JP2024505964A (ja) 2021-02-02 2022-02-02 免疫応答を刺激するための、ポリマーソームと関連づけられたアジュバントの単独使用の方法

Country Status (7)

Country Link
US (1) US20240108720A1 (cg-RX-API-DMAC10.html)
EP (1) EP4288033B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024505964A (cg-RX-API-DMAC10.html)
CN (1) CN117597109A (cg-RX-API-DMAC10.html)
AU (1) AU2022216818A1 (cg-RX-API-DMAC10.html)
CA (1) CA3204785A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022167497A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450060A (zh) * 2012-11-19 2020-07-28 新加坡科技研究局 用于引发对免疫原的免疫响应的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US6835394B1 (en) * 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
WO2009127537A1 (en) 2008-04-17 2009-10-22 GÜNZBURG, Walter Post release modification of viral envelopes
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US10364350B2 (en) 2009-04-20 2019-07-30 Agency For Science, Technology And Research Vesicular system and uses thereof
WO2012018306A1 (en) 2010-08-05 2012-02-09 Agency For Science, Technology And Research A multicompartmentalized vesicular structure and a method for forming the same
CA3170184A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
US20150233800A1 (en) 2012-10-11 2015-08-20 Vin-De-Bona Trading Company Pte Ltd Method of painting microvesicles
CN111450060A (zh) * 2012-11-19 2020-07-28 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016154432A1 (en) 2015-03-24 2016-09-29 VaxLiant, LLC Adjuvant compositions and related methods
US10940201B2 (en) * 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
JP7542257B2 (ja) * 2018-01-25 2024-08-30 エイシーエム バイオラブズ プライベート リミテッド 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
CA3143533A1 (en) * 2019-08-01 2021-02-04 Madhavan Nallani A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome

Similar Documents

Publication Publication Date Title
JP2022543038A5 (cg-RX-API-DMAC10.html)
CN110743008A (zh) 基于纳米颗粒的组合物
EP3432922B1 (en) Orf virus-based platform for vaccine delivery
JP2007231025A (ja) Dna転写ユニットの接種による免疫化
CN1555271A (zh) 白细胞介素-12作为兽医疫苗佐剂
US10512687B2 (en) Compositions and methods for enhanced innate immunity
RU2570732C9 (ru) Усиленный иммунный ответ у видов птиц
JP2002505301A (ja) 新生児免疫のil−12刺激
CN117050986A (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
CN1195297A (zh) 艰难梭菌毒素作为粘膜佐剂
ES2257744T3 (es) Interleuquina-12 como adyuvante para vacunas contra paramyxoviridae.
JP2008517595A (ja) ワクチンと核酸
Su et al. Th1-biased immunoadjuvant effect of the recombinant B subunit of an Escherichia coli heat-labile enterotoxin on an inactivated porcine reproductive and respiratory syndrome virus antigen via intranasal immunization in mice
US20140161836A1 (en) Carious tooth vaccine and preparation method
CN108472255A (zh) 调节胞质dna监测分子的方法
US20240299528A1 (en) A dna plasmid sars-corona virus-2/covid-19 vaccine
JP2024500360A5 (cg-RX-API-DMAC10.html)
CN100509056C (zh) 包含作为佐剂的i型ifn的疫苗和涉及它们的方法
CN1298307A (zh) 通过鼻内接种il-12加强免疫性
JP4578973B2 (ja) 免疫刺激のためのihnvg蛋白質
EP3134118B1 (en) Particulate vaccine formulations for inducing innate and adaptive immunity
JP4091152B2 (ja) 金コロイドを含む核酸調製物
JP2005082581A (ja) 分泌型IgA抗体誘導剤
JP2023549675A5 (cg-RX-API-DMAC10.html)
US20230321230A1 (en) Compositions and Methods for Adjuvanted Vaccines